Accueil   Diary - News   All news SIGNA THERAPEUTICS ANNOUNCES ACHIEVEMENT OF CORPORATE MILESTONES

SIGNA THERAPEUTICS ANNOUNCES ACHIEVEMENT OF CORPORATE MILESTONES

 

 

 

LYON, FRANCE (November 28, 2017) – Signia Therapeutics is an emerging company, spin-off company of VirPath laboratoy/Université Claude Bernard Lyon (UCBL), that proposes an innovative and versatile platform for antiviral drug discovery and repositioning or recycling based on a global targeting of the host cell instead of specific viral molecular determinants.

 

The research strategy is based on the direct exploitation of clinical samples from infected patients and the characterization by NGS of relevant in vivo transcriptomic signatures of infections, in an innovative bedside-to-bench and bench-to-bedside approach. The Company’s capabilities are well adapted to study the pathogenesis of respiratory acute infections and provide a breakthrough methodology for the identification and validation of highly effective and broad-spectrum antivirals.

 

 

I-Lab 2017 Laureate

...

Shareholders

...

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree